NVAX Share Price Performance
US$9.30
1.02 (12.32%)
32.5% undervalued intrinsic discount
US$13.78
Fair Value
Price US$9.30
AnalystConsensusTarget US$13.78
AnalystLowTarget US$7.00
AnalystHighTarget US$25.00
Fair ValueUS$13.78
Share Pricen/a
Novavax, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 124 Fair Values set on narratives written by author
NVAX Community Narratives
AN
Fair Value
·Fair Value US$13.78 32.5% undervalued intrinsic discount
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
0users have liked this narrative
0users have commented on this narrative
60users have followed this narrative
AN
Fair Value
·Fair Value US$7 32.9% overvalued intrinsic discount
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$25 62.8% undervalued intrinsic discount
Pandemic Preparedness Will Drive Next-Generation Vaccine Opportunities Amid Challenges
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Novavax
32.9% overvalued intrinsic discount
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
View narrativeAN
Updated 17 Jun
Novavax
32.5% undervalued intrinsic discount
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
View narrativeAN
Updated 27 Feb
Novavax
62.8% undervalued intrinsic discount
Pandemic Preparedness Will Drive Next-Generation Vaccine Opportunities Amid Challenges
View narrativeAN
Published 20 Aug 2025
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
NVAX: Bearish View Will Hinge On Matrix Licensing Delivering Sustainable Revenue
Fair Value: US$7 32.9% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NVAX: Licensing And Royalty Streams Will Drive Future Cash Generation
Fair Value: US$13.78 32.5% undervalued intrinsic discount
60 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pandemic Preparedness Will Drive Next-Generation Vaccine Opportunities Amid Challenges
Fair Value: US$25 62.8% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Novavax, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -1.50
- -2.56%
- -59.87%
- -152.8%
About NVAX
- Founded
- 1987
- Employees
- 749
- CEO
- WebsiteView website
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
